Interstitial Lung Disease clinical trials at UCSD
3 in progress, 2 open to eligible people
Tibulizumab Systemic Sclerosis Understanding and Response Evaluation (TibuSURE)
open to eligible people ages 18-75
The study is a Phase 2, multi-center, randomized, double-blind, placebo-controlled study to evaluate the effects of tibulizumab over 24 weeks (Period 1) in adult participants with systemic sclerosis, followed by an open-label extension period where all active participants will receive tibulizumab and will be evaluated for an additional 28 weeks (Period 2)
La Jolla, California and other locations
Dry Powder Inhaled Treprostinil in PH
open to eligible people ages 18-80
Study LTI-401 is an open-label, multicenter study which will evaluate the safety and tolerability of LIQ861 in subjects who have WHO Group 1 & 3 PH.
La Jolla, California and other locations
Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis
Sorry, in progress, not accepting new patients
Study RIN-PF-301 is designed to evaluate the superiority of inhaled treprostinil against placebo for the change in absolute forced vital capacity (FVC) from baseline to Week 52.
La Jolla, California and other locations
Last updated: